The estimated Net Worth of Arnold M Baskies is at least $355 Mille dollars as of 26 July 2024. Arnold Baskies owns over 5,000 units of Anixa Biosciences stock worth over $355,350 and over the last 8 years he sold ANIX stock worth over $0. In addition, he makes $0 as Independent Director at Anixa Biosciences.
Arnold has made over 11 trades of the Anixa Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of ANIX stock worth $15,450 on 26 July 2024.
The largest trade he's ever made was buying 20,000 units of Anixa Biosciences stock on 15 July 2021 worth over $78,000. On average, Arnold trades about 5,167 units every 80 days since 2017. As of 26 July 2024 he still owns at least 115,000 units of Anixa Biosciences stock.
You can see the complete history of Arnold Baskies stock trades at the bottom of the page.
Dr. Arnold Baskies M.D. serves as Independent Director of the Company. Dr. Baskies is a surgical oncologist at Virtua Health Systems in southern New Jersey, where he specializes in surgical oncology and general surgery. He trained at Boston University Medical Center and the Surgery Branch of the National Cancer Institute where his early research involved immunotherapy. He has extensive experience in all facets of general surgical problems, with special interests in the treatment of breast cancer, gastrointestinal cancers, thyroid cancer, melanoma, and parathyroid disease, and is a co-investigator in several national studies dealing with breast cancer prevention. He served as chairman of the New Jersey Governor’s Task Force on Early Detection, Prevention and Treatment of Cancer, having created and chaired the cancer control plan for the state from 2000-2016, and is a member of numerous societies, including the Society of Surgical Oncology, the American Society of Breast Surgeons, and the American College of Surgeons. Dr. Baskies has been involved with the American Cancer Society for 40 years. He was awarded the Society’s Silver Chalice Award in 1998 and the Society’s St. George National Award in 2009. He has held leadership positions at many levels of the organization, including service as the first board scientific officer for the American Cancer Society Board of Directors in 2015, and was the chief medical officer and Chairman of the Board of Directors of the former Eastern Division of the American Cancer Society. In 2017, he served as the Chairman of the Board of the American Cancer Society. He presently serves as immediate past chair of the American Cancer Society Board of Directors, having served as a member of the Board of Directors since 2013. He currently chairs the Global Cancer Control Advisory Council for the society. He received a medical degree from Boston University School of Medicine in 1975 and a bachelor of arts degree from Boston University College of Liberal Arts in 1971.
Arnold Baskies is 70, he's been the Independent Director of Anixa Biosciences since 2018. There are 3 older and 7 younger executives at Anixa Biosciences. The oldest executive at Anixa Biosciences, Inc. is Lewis Titterton, 75, who is the Lead Independent Director.
Arnold's mailing address filed with the SEC is C/O ANIXA BIOSCIENCES, INC., 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE,, CA, 95118.
Over the last 6 years, insiders at Anixa Biosciences have traded over $0 worth of Anixa Biosciences stock and bought 834,156 units worth $2,822,805 . The most active insiders traders include Amit Kumar, Lewis H Jr Titterton e Arnold M Baskies. On average, Anixa Biosciences executives and independent directors trade stock every 31 days with the average trade being worth of $78,894. The most recent stock trade was executed by Lewis H Jr Titterton on 30 July 2024, trading 27,226 units of ANIX stock currently worth $84,128.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Anixa Biosciences executives and other stock owners filed with the SEC include: